| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Terry Vance is Director at ENTA. Terry Vance's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $60K at current prices.
The ENTA filings lean toward selling, a net 13,295 shares.
Terry Vance has 15 Form 4 filings on record from February 2015 to March 2026, all as Director at Enanta Pharmaceuticals (ENTA), 2015–2026.
The 15 reported transactions were 12 option or other derivative awards, 1 open-market sale, 1 option exercise and 1 open-market purchase.
Counted by filing, the open-market trades come to 1 purchase worth about $54K and 1 sale worth about $139K.
The only open-market purchase was 2,000 shares of ENTA at an average $27.04 on February 12, 2016, about $54K.
The only open-market sale was 15,295 shares of ENTA at an average $9.12 on December 13, 2023, about $139K. Twelve months later ENTA was down 35%.